In their August 2020 DiaLog newsletter, DiaSys reported that it has become a corresponding member of the IFCC (International Federation of Clinical Chemistry and Laboratory Medicine) Task Force on COVID-19 since June 2020. The task force consists of 12 members in total, among them six from the diagnostic industry sector (Abbott, Beckman, DiaSys, Siemens, Sentinel, Ortho).
The task force has set up guidelines and recommendations to provide regular updates on epidemiology, pathogenesis, and lab diagnostics to manage SARS-CoV-2. It is integral part of their mission to practically harmonize the use of diagnostic tests and biosafety measures in managing specimens. Moreover, the IFCC Task Force organizes international studies to improve knowledge on pathogenesis, diagnostics and therapeutical management of COVID-19. (1-4)
Especially during the actual pandemic, it is essential to guarantee global reliability of all commercially available processes and testing tools. Manufacturers and laboratories may now align their work to the guidelines and recommendations of the IFCC task force on COVID-19 to improve overall routine testing consistency.
DiaSys is honored and will contribute with great commitment to the standardization and optimization of such tests; Professor Dr. Matthias Grimmler, Head of Research & Development who represents DiaSys in the committee states, “We are very proud to collaborate intensively with the IFCC and to demonstrate the innovative and progressive role of DiaSys in global diagnostics.”
Go to IFCC Task Force on COVID-19 for more info or directly to guidelines:
- IFCC Interim Guidelines on Molecular Testing of SARS-CoV-2 Infection.
- IFCC Interim Guidelines on Serological Testing of Antibodies against SARS-CoV-2.
- IFCC Interim Guidelines on Biochemical/Hematological Monitoring of COVID-19 Patients
- IFCC interim guidelines on rapid point-of-care antigen testing for SARS-CoV-2 detection in asymptomatic and symptomatic individuals
DiaSys: An IFCC Corporate Member.
Matthias Grimmler